title: A French multicentric study and review of pulmonary Nocardia spp. in cystic fibrosis patients.
abstract: Some bacterial species recovered from the airways of cystic fibrosis (CF) patients are indisputably associated with lung infections, whereas the clinical relevance of others, such as Nocardia spp., remains unclear. Sixteen French CF cases of colonization/infection with Nocardia spp. were reviewed in order to evaluate the epidemiology, the clinical impact and the potential treatment of these bacteria, and results were compared to those of the literature. Five Nocardia species were identified, Nocardia cyriacigeorgica being the major species (50 % of cases). At first isolation, Nocardia was the sole pathogen recovered in six patients. Seven patients presented pulmonary exacerbation. For 12 patients, antimicrobial treatment against Nocardia was started immediately, mainly based on cotrimoxazole (6 of the 12 cases). In this study, we highlight the heterogeneity of the clinical management of Nocardia spp. in CF. Guidelines for the clinical management of Nocardia infections in CF patients are proposed.
authors.affiliation: Université de Lyon, Lyon, France.
authors.forename: Verónica
authors.initials: V
authors.lastname: Rodriguez-Nava
authors.forename: Stéphane
authors.initials: S
authors.lastname: Durupt
authors.forename: Sandra
authors.initials: S
authors.lastname: Chyderiotis
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Freydière
authors.forename: Judith
authors.initials: J
authors.lastname: Karsenty
authors.forename: Michèle
authors.initials: M
authors.lastname: de Montclos
authors.forename: Philippe
authors.initials: P
authors.lastname: Reix
authors.forename: Isabelle
authors.initials: I
authors.lastname: Durieu
authors.forename: Raphaele
authors.initials: R
authors.lastname: Nove-Josserand
authors.forename: Raphael
authors.initials: R
authors.lastname: Chiron
authors.forename: François
authors.initials: F
authors.lastname: Bremont
authors.forename: Laurent
authors.initials: L
authors.lastname: Têtu
authors.forename: Marlène
authors.initials: M
authors.lastname: Murris
authors.forename: Dominique
authors.initials: D
authors.lastname: Terru
authors.forename: Sylvain
authors.initials: S
authors.lastname: Godreuil
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Bergeron
authors.forename: Jean
authors.initials: J
authors.lastname: Freney
authors.forename: Patrick
authors.initials: P
authors.lastname: Boiron
authors.forename: François
authors.initials: F
authors.lastname: Vandenesch
authors.forename: Hélène
authors.initials: H
authors.lastname: Marchandin
authors.forename: Christine
authors.initials: C
authors.lastname: Segonds
authors.forename: Anne
authors.initials: A
authors.lastname: Doléans-Jordheim
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002353:Carrier State / Q000453:epidemiology* / Q000382:microbiology; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000150:complications*; D005602:France / Q000453:epidemiology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009615:Nocardia / Q000145:classification / Q000302:isolation & purification*; D009617:Nocardia Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination